We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00251550
Recruitment Status : Completed
First Posted : November 10, 2005
Last Update Posted : November 6, 2007
Information provided by:
Eli Lilly and Company

November 8, 2005
November 10, 2005
November 6, 2007
October 2005
Not Provided
To determine the recommended dose of LY231514 and cisplatin combination therapy, Response Rate
Same as current
Complete list of historical versions of study NCT00251550 on ClinicalTrials.gov Archive Site
  • Duration of response
  • Progression free survival
  • Median survival time
  • 1 year survival rate
  • Pulmonary function
  • QOL
  • Safety
  • Plasma concentration
Same as current
Not Provided
Not Provided
Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
Phase I/II Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
To investigate efficacy and safety of pemetrexed combined with cisplatin for chemo-naive patients with Malignant Pleural Mesothelioma.
Not Provided
Phase 1
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Malignant Pleural Mesotherioma
  • Drug: Pemetrexed
  • Drug: Cisplatin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
August 2006
Not Provided

Inclusion Criteria:

  • Inapplicable for radical operation
  • Not received prior systemic chemotherapy
  • Performance status: 0-1

Exclusion Criteria:

  • Having a history of sensitivity to platinum agent, folic acid or vitamin B12
Sexes Eligible for Study: All
20 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time(UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
November 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP